P
P

Pfizer


News

Wall Street ends mixed after punishing week

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) * Ross Stores plunges after cutting 2022 forecast * S&P 500 +0.01%, Nasdaq -0.30%, Dow +0.03% (Updates with details at end of session) By Noel Randewich and Amruta Khandekar May 20 (Reuters) - Wall Street ended mixed on Friday after a volati
G
N
P
T
R
U
U

Switzerland buys Pfizer's 19 antiviral Paxlovid

BERLIN, May 20 (Reuters) - Switzerland signed a contract to buy Pfizer's anti-viral drug Paxlovid to treat Covid-19, it said on Friday. The European country said it had signed a contract to buy 12,000 packages and first treatments for certain at-risk patients would start this month. Reporting by Kirsti Knolle, Editing by Miranda Murray
P

British Business - May 11

May 11 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - Tesla Inc's TSLA.O factory in Shanghai has scaled back production after being hit by supply chain problems, only three weeks after work restarted there. Link - Pf
P
T
T
E

Evonik to invest 8 bln eur by 2030 in high-margin businesses -CEO

* Around 4 bln eur to be invested in Germany * Russia business to come to a standstill * Baby business, C4 unit, Luelsdorf site up for sale BERLIN, May 10 (Reuters) - German chemicals company Evonik EVKn.DE plans to invest 8 billion euros ($8.45 billion) by 2030 to boost growth in its smart materials, specialty additives and nutrition & care units,
P
V

BioNTech's Q1 vaccine sales triple but it still flags full-year decline

FRANKFURT, May 9 (Reuters) - BioNTech's 22UAy.DE first-quarter sales and earnings more than tripled thanks to demand for the COVID-19 vaccine it developed with Pfizer PFE.N , but the German biotech firm is still forecasting a full-year decline in vaccine sales. Quarterly revenues more than tripled from a year earlier to 6.37 billion euros ($6.73 bi
P

BioNTech posts tripled Q1 vaccine sales but still flags full-year decline

FRANKFURT, May 9 (Reuters) - BioNTech 22UAy.DE said first-quarter sales and earnings more than tripled thanks to demand for the COVID-19 vaccine it developed with Pfizer PFE.N , but the German biotech firm reaffirmed its forecast for a full-year decline in vaccine sales. First-quarter revenues more than tripled from the year-earlier period, to 6.37
P

EU regulator hopes to approve COVID variant-adapted vaccines by autumn

May 5 (Reuters) - The European Union's drug regulator said on Thursday it hoped to have vaccines adapted to address coronavirus variants, such as Omicron, approved by September. "Our priority is to ensure that adaptive vaccines are possibly approved by September at the latest to be ready for the rollout of new immunisation campaigns in the EU in th
P

Wall St Week Ahead-Rocky stock market faces Fed test with eyes on tightening plans

By Lewis Krauskopf NEW YORK, April 29 (Reuters) - A volatile stock market faces a critical test next week, when the U.S. Federal Reserve is expected to raise interest rates and give more insight on its plans for tightening monetary policy to fight surging inflation. Worries over an increasingly hawkish Fed have helped drag the benchmark S&P 500 ind
P
S
U

Wall St Week Ahead-Rocky stock market faces Fed test with eyes on tightening plans

(Updates with further market data) By Lewis Krauskopf NEW YORK, April 29 (Reuters) - A volatile stock market faces a critical test next week, when the U.S. Federal Reserve is expected to raise interest rates and give more insight on its plans for tightening monetary policy to fight surging inflation. Worries over an increasingly hawkish Fed have he
A
P
S
U

Wall St Week Ahead-Rocky stock market faces Fed test with eyes on tightening plans

By Lewis Krauskopf NEW YORK, April 29 (Reuters) - A volatile stock market faces a critical test next week, when the U.S. Federal Reserve is expected to raise interest rates and give more insight on its plans for tightening monetary policy to fight surging inflation. Worries over an increasingly hawkish Fed have helped drag the benchmark S&P 500 ind
P
S
U

Wall Street Journal - April 27

April 27 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - U.S. Vice President Kamala Harris tested positive for COVID-19 on Tuesday, her press secretary, Kirsten Allen, said. on.wsj.com/3EP4CCf - Mattel Inc MAT.O has held talks with private-equi
M
P

India to face more power cuts due to coal shortage, soaring demand

* India FY23 power output seen 15.2% up, coal-fired power over 17% Coal trains to utilities from April 1-6 at 379/day vs 453 needed Coal India FY23 supply target to power sector 565 mln T * Total FY23 local coal requirement at 760 mln T By Sudarshan Varadhan CHENNAI, April 12 (Reuters) - India is likely to face more power cuts this year as utilitie
P

India to face more power cuts due to coal shortage, soaring demand

* India FY23 power output seen 15.2% up, coal-fired power over 17% Coal trains to utilities from April 1-6 at 379/day vs 453 needed Coal India FY23 supply target to power sector 565 mln T * Total FY23 local coal requirement at 760 mln T By Sudarshan Varadhan CHENNAI, April 12 (Reuters) - India is likely to face more power cuts this year as utilitie
P

UK Stocks-Factors to watch on April 12

April 12 (Reuters) - Britain's FTSE 100 index .FTSE is seen opening lower on Tuesday, with futures FFIc1 down 0.59%. * EASYJET: Britain's easyJet EZJ.L said it had outperformed its first-half expectations despite the challenges of COVID-19 and rising fuel prices, with capacity ramping up to reach 80% of pre-pandemic levels in March and a recovery i
E
M
P
P
P
U
P

UK Stocks-Factors to watch on April 12

April 12 (Reuters) - Britain's FTSE 100 index .FTSE is seen opening lower on Tuesday, with futures FFIc1 down 0.78%. * PARKER-HANNIFIN-MEGGITT: U.S. engineering and aerospace group Parker-Hannifin PH.N on Monday won EU antitrust approval for its 6.3-billion-pound ($8.2 billion) planned acquisition of Britain's Meggitt MGGT.L after pledging to sell
E
M
P
P
U
P

Wall Street Journal - April 8

April 8 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - Walmart Inc WMT.N is raising starting pay for in-house truck drivers to as much as $110,000 a year and expanding a program that trains its existing workers to become drivers. Link - Tesla
B
P
T

Stocks rally late, 10-yr U.S. Treasury yield touches 3-yr high

* U.S. stocks end higher * 10-year Treasury yield rises * Investors still digesting Fed signals (New throughout, updates prices, market activity and comments; new byline, changes dateline, previous LONDON) By Caroline Valetkevitch NEW YORK, April 7 (Reuters) - Stock indexes mostly rose on Thursday as investors snapped up beaten-down shares, while t
E
P
U
G
U
U
O
B

New York Times business news - March 30

March 30 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - Federal regulators authorized second booster shots of the Pfizer Inc PFE.N /BioNTech SE 22UAy.DE and Moderna Inc MRNA.O coronavirus vaccines on Tuesday for everyone 50 and older
P

German health minister urges EU to clear 2nd booster for elderly

By Andreas Rinke and Ludwig Burger BERLIN, March 29 (Reuters) - Germany's health minister said on Tuesday he would urge the European Union to back a fourth COVID-19 shot for people over the age of 60 years to boost immunity in the absence of vaccines that specifically protect against the Omicron variant. Pointing to data from Israel, minister Karl
P

S.Africa two-thirds of way to $100 bln investment goal -president

* S.Africa seeking 1.4 trillion rand over five years * Country has struggled from slow growth, pandemic * New investments span manufacturing, mining, pharma sectors (Updates with new investment figures, additional quote from Ramaphosa) By Joe Bavier JOHANNESBURG, March 24 (Reuters) - South Africa is close to reaching a five-year target for new inve
N
P
A



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.